“Clinically important response rates, combined with the low adverse event rate observed with this combination, opens the possibility for this CAVATAK with ipilimumab combination to move into a pivotal registration study in patients who have failed prior checkpoint inhibitor therapy.”
Moving forward in right direction, hope new advisory team hard at work designing a trial.
